SEARCH

SEARCH BY CITATION

References

  • 1
    Bhasin S. Clinical review: androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 12211225
  • 2
    Burris AS, Banks SM, Carter CS, Davidson JP, Sherins RJ. A long-term prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297304
  • 3
    Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994; 23: 857875
  • 4
    Arver S, Dobs AS, Meikle AW et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: 727737
  • 5
    Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 26702677
  • 6
    Wang C, Nieschlag E, Swerdloff RS et al. ISA, ISSAM, EAU, EAA, and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol 2008; 159: 507514
  • 7
    Behre HM, Boymeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994; 40: 341349
  • 8
    Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. A randomized controlled trial. JAMA 2006; 296: 23512361
  • 9
    Meikle AW, Mazer NA, Moellmer JF et al. Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metabol 1992; 85: 623628
  • 10
    Raynaud JP, Legros JJ, Rollet J et al. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for one year to hypogonadal men. J Steroid Biochem Molec Biol 2008; 109: 168176
  • 11
    Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482492
  • 12
    Fiet J, Giton F, Belanger A et al. Development of a highly sensitive and specific new testosterone time–resolved fluoroimmuno-assay in human serum. Steroids 2004; 69: 461471
  • 13
    Giton F, Fiet J, Guéchot J et al. Serum bioavailable testosterone: assayed or calculated? Clin Chem 2006; 52: 474481
  • 14
    Giton F, Urien S, Born C et al. Determination of bioavailable T (Non Sex Hormone Binding Globulin [SHBG]-Bound T) in a population of healthy French Men: influence of Androstenediol on T Binding to SHBG. Clin Chem 2007; 53: 21602168
  • 15
    Heinemann LA, Zimmermann T, Vermeulen A, Thiel C. A new ‘Aging Male's Symptoms’ (AMS) rating scale. Aging Male 1999; 2: 105114
  • 16
    Food and Drug Administration. Centre for Drug Evaluation and Research. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. Rockville: Guidance for industry, 1999
  • 17
    Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. J Steroid Biochem Mol Biol 2008; 109: 177184
  • 18
    Raynaud JP, Augès M, Liozno L, Turlier V, Lauze C. Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditions. Int J Pharm 2009; 22: 2832
  • 19
    Raynaud JP, Tichet J, Born C et al. Aging Male Questionnaire in normal and complaining Men. J Sex Med 2008; 5: 27032712
  • 20
    Jordan W. Allergy and topical irritation associated with transdermal testosterone application: a comparison of scrotal and non scrotal transdermal system. Am J Contact Dermat 1997; 8: 108113
  • 21
    Wilson D, Kaidbey K, Boike S, Jorkasky D. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20: 2992306
  • 22
    Meikle AW, Arver S, Dobs AS et al. Prostate size in hypogonadal men treated with a non scrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191196
  • 23
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310320
  • 24
    Bonne C, Raynaud JP. Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 1975; 26: 227232
  • 25
    Rhoden EL, A Morgentaler A. Influence of demographic factors and biochemical characteristicson the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006; 18: 201205
  • 26
    Raynaud JP, Colle M, Pujos-Gautraud M, Lemaire A, Auzerie J, Gardette J. Comparison of oral versus transdermal testosterone supplementation in hypogonadal men. Horm Mol Biol Clin Invest 2010; 2: 301309
  • 27
    Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99106
  • 28
    Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 12561260
  • 29
    Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostate Disease 2006; 9: 1418
  • 30
    Raynaud JP. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol 2009; 114: 96105
  • 31
    Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555563